Investor Presentation Highlights Commercial ProgressSeer, Inc. (NASDAQ:SEER) shares surged 30% on Monday after the proteomics ...

Seer is Delivering Clear Progress Against its Strategic Plan and Maintaining Focus on Cost Discipline, Governance Rigor and Product Innovation ...

The stock was up 39% to $2.25 in late Tuesday morning trading. The shares are now down less than 1% in the past 52 weeks. Farokhzad, who is also the biotechnology company's chair, made the unsolicited ...

(Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that it has received an unsolicited, non-binding proposal from Omid Farokhzad, M.D., Seer’s Chair ...

The chief executive officer of Seer has offered to buy the company for $2.45 a share in cash, plus two contingent value rights, the biotechnology company said. Seer on Thursday said that CEO Omid ...

On June 25, 2026, the European Patent Office (EPO) concluded that European Patent No. EP4056263 will be maintained on the basis of claims covering particle-based enrichment for proteomics, and on June ...

Seer ( (SEER)) just unveiled an update. On July 2, 2026, Seer, Inc. announced it had received an unsolicited, non-binding proposal from its chair and chief executive officer, Omid Farokhzad, M.D., to ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Seer, Inc. ("Seer" or "the Company") (NASDAQ: SEER) for ...